One of the most important stories in the biopharma industry has been the rise of GLP-1 agonists for treating obesity. Novo Nordisk A/S’s GLP-1 agonist Ozempic/Wegovy (semaglutide) and Eli Lilly and Company’s GIP/GLP-1 agonist Mounjaro/Zepbound (tirzepatide) are taking a dominant role in the drug market overall and will likely continue to be a major driver of sales over the next several years, according to IQVIA’s latest medication usage report.
The report, released on 7 May, found that the US prescription drug market at net prices grew overall to $435bn...